Abiraterona en cáncer de próstata hormono-sensible metastásico

6 / 32

LATITUDE: primary efficacy endpoints, rPFS
Patients in the ADT+AA+P group had a 53% reduction in the
risk of radiographic progression or death
Fizazi K et al. N Engl J Med 2017;377(4):352-360
LATITUDE: primary efficacy endpoints, rPFS
Patients in the ADT+AA+P group had a 53% reduction in the
risk of radiographic progression or death
Fizazi K et al. N Engl J Med 2017;377(4):352-360